YZY Biopharma Y225 Patent Secures Hemlibra Biosimilar Pathway in China
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high‑concentration antibody formulation for...
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) announced today that its high‑concentration antibody formulation for...
Wuhan YZY Biopharma Co., Ltd. (HKG: 2496) today disclosed interim data from its Phase II clinical...
China-based Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced the presentation of results from...
Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced that it has granted Chi Ta...
Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced...
A cohort of Chinese biopharmaceutical companies, including Wuhan YZY Biopharma Co., Ltd (HKG: 2496), Suzhou...
Wuhan YZY Biopharma Co., Ltd (HKG: 2496), a biopharmaceutical company based in China, has announced...
Wuhan YZY Biopharma Co., Ltd, (HKG: 2496) a biopharmaceutical company specializing in targeted cancer drugs...
China-based Wuhan YZY Biopharma Co., Ltd, a biopharmaceutical company focused on targeted cancer drugs and...
China Medical System Holdings (CMS; HKG: 0867) announced an asset transfer agreement with Wuhan YZY...
China’s Chongqing Lummy Pharmaceutical Co., Ltd (SHE: 300006) announced the termination of its strategic partnership...
China-based Wuhan YZY Biopharma Co., Ltd has reportedly raised RMB 200 million (USD 29.8 million)...